OHSU Researchers Secured Federal Gene Therapy Funding

The $7.5 million grant supports development of new gene therapies for rare kidney diseases at the Portland institution.

Updated on Oct. 12, 2026 in Biotech

OHSU Researchers Secured Federal Gene Therapy Funding

Live Poll

Should the federal government increase funding for gene therapy research to cure rare diseases?

Researchers at the Oregon Health and Science University have been awarded $7.5 million in federal funding to advance gene therapy research. The project focuses on developing potential cures for rare kidney conditions.

Why it matters

The research aims to move beyond symptom management by delivering healthy genes to diseased cells, potentially offering the first cures for these rare conditions. This effort could fundamentally change the treatment landscape for patients facing currently incurable kidney diseases.

The therapy functions by using harmless viruses to deliver healthy gene copies to damaged kidney cells. Preliminary testing has been successfully conducted on mice and primates to validate the delivery mechanism.

The players

Oregon Health and Science University

This public research university based in Portland is a hub for medical and scientific innovation in the Pacific Northwest.

The details

The team at Oregon Health and Science University will utilize the funds to refine their delivery method for genetic material. Current treatments for these conditions typically focus on managing symptoms, but this approach seeks to address the underlying genetic cause.

Clinical trials for the new gene therapy are projected to begin within four years.

The Tech Race

This research follows a pattern set by the FDA approval of Luxturna for inherited retinal disease by using viral vectors to correct genetic defects. It marks a significant step in the biotech sector's ongoing transition toward curative gene-editing technologies.

While the therapy is currently in early stages, success could eventually lead to new curative options for those suffering from chronic kidney conditions. Patients should monitor future trial announcements for potential participation opportunities.

The takeaway

Gene therapy represents a shift toward addressing disease at the molecular level rather than merely treating the resulting health issues. Early-stage successes in animal models provide a crucial foundation for future human clinical applications.